Abstract:The protein-protein interactions (PPIs) in the biological systems are important to maintain a number of cellular processes. Several disorders including cancer may be developed due to dysfunction in the assembly of PPI networks. Hence, targeting intracellular PPIs can be considered as a crucial drug target for cancer therapy. Among the enormous and diverse group of cancer-enabling PPIs, the Hsp90-Cdc37 is prominent for cancer therapeutic development. The successful inhibition of Hsp90-Cdc37 PPI interface can be an important therapeutic option for cancer management. In the current study, a set of more than sixty thousand compounds belong to four databases were screened through a multi-steps molecular docking study in Glide against the Hsp90-Cdc37 interaction interface. The Glide-score and Prime-MM-GBSA based binding free energy of DCZ3112, standard Hsp90-Cdc37 inhibitor were found to be -6.96 and -40.46 kcal/mol, respectively. The above two parameters were used as cut-off score to reduce the chemical space from all successfully docked molecules. Furthermore, the in-silico pharmacokinetics parameters, common-feature pharmacophore analyses and the molecular binding interactions were used to wipe out the inactive molecules. Finally, four molecules were found to be important to modulate the Hsp90-Cdc37 interface. The potentiality of the final four molecules was checked through several drug-likeness characteristics. The molecular dynamics (MD) simulation study explained that all four molecules retained inside the interface of Hsp90-Cdc37. The binding free energy of each molecule obtained from the MD simulation trajectory was clearly explained the strong affection towards the Hsp90-Cdc37. Hence, the proposed molecule might be crucial for successful inhibition of the Hsp90-Cdc37 interface.Communicated by Ramaswamy H. Sarma.

Hotspot Identification and Drug Design of Protein-Protein Interaction Modulators Using the Fragment Molecular Orbital Method

A compound-based computational approach for the accurate determination of hot spots

PPI-hotspotID for detecting protein-protein interaction hot spots from the free protein structure

Protein-protein interface analysis and hot spots identification for chemical ligand design.

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Target-specific design of drug-like PPI inhibitors via hot-spot-guided generative deep learning

Benchmark Study Based on 2P2I(DB) to Gain Insights into the Discovery of Small-Molecule PPI Inhibitors

Chemical-Protein Interactome and Its Application in Off-Target Identification

Mapping, Structure and Modulation of PPI

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering

Exploring protein hotspots by optimized fragment pharmacophores

A comprehensive dataset of protein-protein interactions and ligand binding pockets for advancing drug discovery

What Makes a Good Protein–Protein Interaction Stabilizer: Analysis and Application of the Dual-Binding Mechanism

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

In silico identification of small molecule modulators for disruption of Hsp90-Cdc37 protein-protein interaction interface for cancer therapeutic application

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

Targeting Protein-Protein Interaction by Small Molecules

Revisiting Pyrimidine-Embedded Molecular Frameworks to Probe the Unexplored Chemical Space for Protein-Protein Interactions

Development of R7BP inhibitors through cross-linking coupled mass spectrometry and integrated modeling

Hotspots API: A Python Package for the Detection of Small Molecule Binding Hotspots and Application to Structure-Based Drug Design

Interface-aware molecular generative framework for protein-protein interaction modulators